A team developed the catGRANULE 2.0 ROBOT, a machine-learning algorithm to predict protein behavior linked to ...

The first study participant was enrolled in July 2024, and since that time, the consortium has recruited over 300 ...

A research group led by Gian Gaetano Tartaglia, Principal Investigator at the Italian Institute of Technology (IIT ...

ALS, or amyotrophic lateral sclerosis, is a fatal neurodegenerative disease that gradually robs individuals of their ability to walk, talk, eat, and eventually breathe.

People turning 65 should know the key dates for enrolling in Medicare. Learn about Medicare Advantage plans and other options ...

Iowa Wild fans have the chance to cheer on their team, possibly score some great Star Wars-themed gear, and support an ...

SNUG01 is a first-in-class targeted gene therapy that’s designed to increase the levels of TRIM72, a protein with ...

Unlearn® and Trace Neuroscience are partnering to use Unlearn’s Digital Twin Generator for Trace Neuroscience Phase 1/2 ALS clinical trial.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing ...

All intellectual and work property derived from DiagnaMed’s research activities in amyotrophic lateral sclerosis (ALS) and its Orphan Drug Designation (ODD) for molecular hydrogen in the treatment of ...

Revive Therapeutics (RVVTF) it has entered into an asset purchase agreement dated March 31 with DiagnaMed to acquire the full rights to ...